Vanessa Research (VR), a biomedical company pioneering innovative products in areas of unmet needs, has secured the CE Marking, Module C Certificate, for its KLAREX brand KN95 masks. This certification attests to the conformity of the quality of the KLAREX KN95 masks. The Module C Certificate allows the masks to be sold across Europe, which further supports the company’s mission to provide public health products where they are needed most.
The superior KLAREX KN95 masks, with 4-layers instead of the conventional 3-layers, are currently sold and distributed in the USA directly by VR and through its eCommerce website www.klarexhealth.com.
VR is a biomedical company founded on the desire to “give hope where none existed” by making an impact on healthcare markets that are often overlooked. Their continually expanding pipeline of innovative pharmaceuticals, medical devices, and consumer and public health products reflects the company’s inventive nature and commitment to delivering solutions that increase access to quality care. The company’s flagship product, Shylicine™, is the first-ever drug developed to treat the rare, lethal microvillus inclusion disease. The company’s other notable brands include HunaZine™, KLAREX®, SEAL N’FREEZE®, and SOLAWARE®.
VR, a University of Connecticut Technology Incubation Program participant, has global offices in Hungary, Spain and Germany in addition to its Hamden, Conn. corporate campus.
P.O. Box 185755
Hamden, Conn. 06518
+1 203 836 8424